Pharmacology resources - presentation: David Back

Ensuring Effective Drug Levels Click here to start

Table of Contents	Author: D Back
Ensuring Effective Drug Levels PK Principles 450-Glycoprotein Pharmacokinetic – Surrogate Relationship Pharmacokinetic Profile of a Single PI Administered Twice Daily Inhibitory Quotient (= Concentration/IC50) In-vitro IC50 and IC95 Effect of Adding Ritonavir to Indinavir Steady-state Indinavir Plasma Concentrations First Pass Metabolism Inhibition of First Pass Metabolism Pharmacoenhancement ABT-378 ABT-378 Plasma Concentrations in Patients Following 400/100 mg bd Regimen Protein-binding Corrected IC95 Determinations for PIs Cmin/IC95 for PIs Cmin/IC95 Ratios for Currently Available PIs (IC95 Values Determined in the Presence of 50% Human Serum) ABT-378 Pharmacokinetic Profiles Inhibitory Quotient (Cmin / ?) for Amprenavir Protease Inhibitors – bd Regimens ABT-378/r Interactions with NNRTIs and PIs Treatment Failure Role of Transporters Issues to Clarify